The prospect of using endothelial progenitors is currently hampered by their low engraftment upon transplantation. We report that mesenchymal stem/stromal cells (MSCs), independent of source and age, improve the engraftment of endothelial colony forming cells (ECFCs). MSC coculture altered ECFC appearance to an elongated mesenchymal morphology with reduced proliferation. ECFC primed via MSC contact had reduced selfrenewal potential, but improved capacity to form tube structures in vitro and engraftment in vivo. Primed ECFCs displayed major differences in transcriptome compared to ECFCs never exposed to MSCs, affecting genes involved in the cell cycle, up-regulating of genes influencing mesenchymal transition, adhesion, extracellular matrix. Inhibition of NOTCH signaling, a potential upstream regulator of mesenchymal transition, in large part modulated this gene expression pattern and functionally reversed the mesenchymal morphology of ECFCs. The collective results showed that primed ECFCs survive better and undergo a mesenchymal transition that is dependent on NOTCH signaling, resulting in significantly increased vasculogenic potentialof endothelial colony-forming cells in a mesenchymal niche improves engraftment and vasculogenic potential by initiating mesenchymal transition orchestrated by NOTCH signaling. FASEB J. 31, 610-624 (2017). www.fasebj.org
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the developed world (1, 2) . Restoring blood supply to ischemic tissues is an essential goal for successful treatment of CVD. In 1997, Asahara et al.
(3) described the initial concept of an endothelial progenitor cell (EPC) with potential to home to ischemic tissues and contribute to vascularization. Although bone marrow (BM) was initially considered the main source of EPCs (4), a more stringent definition to exclude hematopoietic cells (5, 6) and restriction of their lineage to endothelium only, led to EPC isolation from other tissues. In particular, ex vivo culture of highly proliferative populations of late outgrowth endothelial colony-forming cells (ECFCs) from human cord blood added further stringency to this definition and established a self-renewal hierarchy among endothelial cells (ECs) (7) . The in vivo vasculogenic potential of these cells (8) (9) (10) raised hope that they could be used in clinical trials for cell therapy. Recently, we and others isolated ECFCs from the human term placenta as a promising alternative source for cardiovascular cell-based therapies (11) (12) (13) . This further reinforces the possibility of large scale ECFC isolation for therapeutic application.
Despite their availability, vascularization by ECFCs is hampered by their restricted cell engraftment and function after transplantation (14, 15) . This obstacle hampers clinical translation and argues against their potential advantage ABBREVIATIONS: AdBM, adult-bone marrow; BM, bone marrow; CM, conditioned medium; CVD, cardiovascular disease; DAPT, N-[N-(3,5difluorophenacetyl-l -alanyl)]-(S)-phenylglycine t-butyl ester; EBM, endothelial basal medium; EC, endothelial cluster; ECFC, endothelial colony-forming cell; ECM, extracellular matrix; eGFP, enhanced green fluorescent protein; EGM, endothelial growth medium; EMT, epithelial/ endothelial-to-mesenchymal transition; EPC, endothelial progenitor cell; FACS, fluorescence-activated flow cytometry; FBS, fetal bovine serum; fBM, first trimester fetal bone marrow; fPL, fetal placental; HPP, high proliferative potential; LPP, low proliferative potential; mPL, maternal placental; MSC, mesenchymal stem/stromal cell; ns, nonsignificant; qPCR, quantitative PCR; SDF-1, stromal cell-derived factor over other cell types, such as mesenchymal stem/stromal cells (MSCs) (8, 16) or leukocyte/monocyte (17) preparations that instead almost exclusively work through paracrine proangiogenic activity.
Recent studies suggest a key role for mesenchymal cells and particularly MSCs in EPCs' regenerative potential (18) (19) (20) . During development, ECs reside in a mesenchymal niche, and their development is influenced by their mesenchymal surroundings (21, 22) . In adults, ECs are also in close contact with pericytes in most mature vessels (23) , and mesenchymal cell malfunction results in several vascular disorders (24, 25) . It therefore appears that contact with mesenchymal cells constitutes a niche where endothelial cell function is stabilized. Furthermore, a growing body of evidence suggests that pericytes are the cells of origin of MSCs (24, 26, 27) . This finding has supported strategies of cotransplantation of MSCs with EPCs. Despite these early studies (18) (19) (20) , the short and long-term consequences of MSC/ECFC codelivery on EC self-renewal and progenitor function, as well as the molecular mechanisms at play, have not been characterized.
To understand the potential benefit of cotransplantation strategies, we hypothesized that an ex vivo mesenchymal niche would support ECFC maintenance and function upon transplantation. In systematically investigating this hypothesis, we determined the effect on ECFCs of MSCs of different ages and sources. Our findings suggest that exposure to a mesenchymal niche primes ECFCs toward a more differentiated phenotype, enhancing their engraftment and vasculogenic potential in vivo.
MATERIALS AND METHODS

Ethics statement
Human and animal ethics approval was obtained from the University of Queensland and Royal Brisbane and Women's Hospital. Human term placentas were obtained from healthy mothers during elective caesarean delivery after written informed consent. Twin or pathologic pregnancies were excluded. 
Preparation of stem/progenitor cells
GFP tagging of ECFCs
To distinguish between ECFCs and MSCs in dual-cell experiments, a dual bioluminescent (mutant of luciferase with bioluminescent properties) and fluorescent ECFC line was created by using double reporter lentivectors, according to the manufacturer's protocol (System Biosciences, Mountain View, CA, USA). This method allows differentiation of ECFCs from MSCs. After transduction, eGFP highly positive cells were sorted with the fluorescence-activated flow cytometry (FACS) Aria 11u system (BD Biosciences, San Jose, CA, USA) and used for expansion in culture and experimentation.
Implantation of Matrigel containing embedded cells
ECFCs were cultured in EGM2, and on harvest, 2.5 310 5 , 5 3 10 5 , or 1 3 10 6 cells were suspended in 150 ml Matrigel (BD Biosciences) on ice and subcutaneously injected into anesthetized rag1 2/2 mice (8-12 wk old, C57BL/6 genetic background, n = 3 in each group) that are developmentally devoid of T and B cells. To reduce the number of mice and also variation in implant conditions, 4 grafts (2 tests, 2 controls) were implanted in each anesthetized mouse. At 1, 4, 7, and 14 d after graft-recipient mice were euthanized, and the Matrigel plugs were harvested. In a dual-cell system injection, ECFCs and MSCs were cultured separately in EGM2 and DMEM, respectively. Then, ECFCs alone (5 3 10 5 cells; n = 6 mice) or MSCs alone (5 3 10 5 cells; n = 3 mice for each MSC type) or a mixture of ECFCs-MSCs (total 1 3 10 6 cells, 1:1 ratio, n = 5 mice for each MSC type) were suspended in Matrigel and subcutaneously implanted into rag1 2/2 mice.
Immunohistochemistry evaluation of Matrigel plugs
Upon harvest, implants were fixed in 4% paraformaldehyde, soaked in 20% sucrose, and embedded in optimal cutting temperature medium (Tissue Tek, Torrance, CA, USA). Cryosections (8 mm) were prepared and stained with rabbit-anti-human lamin A/C antibody (1:250 dilution; Abcam, Cambridge, United Kingdom) to visualize donor cells under standard immunohistochemistry protocols. In brief, slides were incubated for 2 h with primary antibodies. Next, they were washed with PBS/0.5% Tween 3 times and incubated with secondary antibodies at room temperature for 45 min. They were again washed 3 times with PBS/0.5%Tween before mounting in Prolong Gold reagent with DAPI (Thermo Fisher Scientific) and observed under an Axio microscope (Zeiss, Jena, Germany).
For immunofluorescence evaluation of human-derived vessels in the implantation area, mouse-anti-human CD144 (1:100; BD Biosciences), rat-anti-human/mouse CD49f (1:100; Bio-Legend, London, United Kingdom), or mouse-anti-human CD31 (1:50; BD Biosciences) antibodies were used. Human derived vessels were evaluated by colocalization of human-specific lamin A/C nuclear marker or the GFP-ECFC with anti-human CD144 (BD Biosciences).
In vitro coculture assay
To assess the impact of MSCs on ECFC survival, we cocultured cells in EGM2 or to mimic the in vivo situation upon cell implantation, we coseeded cells in endothelial basal medium (EBM; Lonza), without addition of serum or growth factors. Adult (Ad)BM-MSCs and ECFCs were cocultured together in T75 flasks with 1:1 ratio at a final concentration of 5 3 10 5 cells; ECFCs were cultured alone in EBM or EGM2 as a control. After 48 h, cells were collected and counted manually as well as by the Gallios flow cytometer (Beckman Coulter, Fullerton, CA, USA). The number of ECFCs was analyzed with Kaluza flow cytometry analysis software (Beckman Coulter). To assess the impact of cell-cell contact on ECFC survival, Transwell chambers with a 0.4-mm pore size membrane (Corning, Inc., Corning, NY, USA) were used. MSCs were seeded on the top and ECFCs were cultured in the bottom in separate plates with 0.5 3 10 5 cell concentration and after 4 h of coculture, the medium was exchanged for EBM. After 48 h, the number of ECFCs was counted. To appreciate the contribution of MSC-secreted factors on ECFCs, 5 3 10 5 MSCs were seeded in EBM, and after 48 h the, conditioned medium (CM) was collected, centrifuged to remove any dead cells, and filtered through a 0.22-mm filter. The CM was immediately transferred on top of the ECFCs or concentrated in an Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-3 membrane (molecular weight cut off, 3 kDa; EMD-Millipore, Waltham, MA, USA) at 4000 g for 30 min. The ECFCs were plated in 6-well plates (5 3 10 4 /well) and placed in the incubator, and the number of ECFCs was measured after 48 h.
Transplantation of ECFCs with MSC-derived CM
As above, MSC-CM was harvested from MSCs after a 48 h culture in EBM and concentrated 50-fold. Concentrated CM (100 ml) was mixed with ECFC (5 3 10 5 ) in 150 ml Matrigel and subcutaneously injected into anesthetized rag1 2/2 mice (n = 3 mice). A second group received subcutaneous injections of ECFCs alone (5 3 10 5 cells; n = 3 mice), and the third group was injected with 
GAACCTCTCGGCTTTCCCG AGCAAGACGTTCAGTCCTGTC AdBM-MSCs and ECFCs together (5 3 10 5 cells each; ratio 1:1; n = 3 mice). After 7 d, the mice were euthanized, and the Matrigel plugs were harvested and assessed for ECFC count.
Generation and transplantation of primed ECFCs
MSC-ECFC cocultures were maintained in EGM-2 for 4 d, cells were collected and washed with PBS, and the cell pellet was suspended in magnetic-activated cell sorting buffer and stained for mouse PE/Cy5 conjugated anti-human CD90 antibody (BioLegend). GFP + CD90 2 cells were sorted with a FACS machine. These ECFCs were called primed ECFCs. Sorted cells (2.5 3 10 5 ) were resuspended in 150 ml Matrigel and subcutaneously injected into the anesthetized rag1 2/2 mice (n = 3). As a control, nonprimed ECFCs were implanted alone (n = 3 mice) or with AdBM-MSCs (n = 3). After 7 d, the mice were euthanized and the Matrigel plugs harvested.
Single-cell clonogenic assay
Single-cell clonogenic assays were performed as previously reported (7) . First, AdBM-MSCs and ECFCs were cocultured in EGM-2 for 4 d and GFP + CD90 2 cells then sorted. As a control, ECFCs were cultured in EGM-2 for 4 d and the GFP + CD90 2 cells sorted. On sorting, a single cell (GFP + CD90 2 ) was cultured in a precoated 96-well cell culture plate, coated with collagen type 1 and containing EGM-2. For each condition 384 cells were cultured in 4 plates, 1 cell per well (n = 5 independent samples). Plates were incubated in a humidified incubator at 37°C in 5% CO 2 , and the medium was changed twice weekly. After 2 wk, each single well was examined with an inverted microscope (Nikon, Sydney, NSW, Australia). Colonies were scored as endothelial clusters (,50 cells; ECs), low proliferative potential EPCs (LPP; 50-2000 cells), and high proliferative potential EPCs (HPP; .2000 cells).
In vitro tube-formation assay
Twenty-four-well plates (Nunc, Roskilde, Denmark) were initially precoated with 200 ml Matrigel and incubated for 30 min. Then, 1 3 10 4 primed or nonprimed ECFCs were cultured in each well (n = 4 independent samples). Plates were placed in the IncuCyte Zoom (Essen BioScience, Ann Arbor, MI, USA) and images taken every 2 h. The number of tubes per field of view was counted.
RNA isolation and microarray analysis
ECFCs were cultured with or without AdBM-MSCs in EGM-2 for 4 d and then GFP + CD90 2 cells were sorted (n = 5 independent samples). Total RNA was extracted with the RNeasy Mini Kit (Qiagen, Chadstone Centre, VIC, Australia). RNA quality and quantity were analyzed with the 2100 Bioanalyzer (Agilent Technologies, Mulgrave, VIC, Australia). Total RNA was conducted for use on the microarray by using the Human Gene Array 2.0 ST (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's protocols. Microarray analysis was performed with GeneSpring (Agilent Technologies) software.
Real-time quantitative PCR
Total RNA was extracted and reverse transcribed to cDNA with the Superscript III Reverse Transcription Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Quantitative PCR (qPCR) was conducted with 0.5 mM of forward and reverse primers with FastStart SYBR Green Master Mix per reaction (Roche Applied Sciences, Melbourne, VIC, Australia) in a 7700 Sequence Detection System with SDS, v1.9 software (Thermo Fisher Scientific). Primer sequences are listed in Table 1 . All PCR samples were run from at least 3 separate cell culture experiments in triplicate.
Assessment of NOTCH pathway impact on ECFC function
To assess the impact of the NOTCH pathway on ECFC function, ECFCs were cultured with or without MSCs and incubated with N-[N-(3,5-difluorophenacetyl-l -alanyl)]-(S)phenylglycine t-butyl ester (DAPT; Abcam), a well-described g-secretase inhibitor, or DMSO (control). We used 50 mM DAPT based on recent work in our laboratory as the optimum concentration to block the NOTCH pathway (30) . After 4 d, GFP + CD90 2 cells were sorted and subjected to in vitro tube formation and single-cell clonogenic assays, as well as total RNA extraction for qPCR. All DAPT treatment assays were run from at least 3 separate cell culture experiments in triplicate.
Statistical analysis
Analyses were performed using Prism, v6.04 software (Graph-Pad, La Jolla, CA, USA). Descriptive statistics are expressed as means 6 SD. Groups were compared by Student t tests and 1-or 2-way ANOVA for parametric variables. The Mann-Whitney U test was used to compare nonparametric variables. Values of P , 0.05 indicated statistical significance.
RESULTS
MSCs from different sources improve ECFC engraftment in vivo
Time-course monitoring showed only a few cells could survive upon ECFC engraftment (Supplemental Fig. 1A-C) . Then, GFP-tagged ECFCs were coimplanted with human AdBM-MSCs, first trimester fBM-MSCs, fPL-MSCs, or mPL-MSCs, and compared to ECFCs alone (Fig. 1A) .
In rag1 2/2 mice, there was a clear difference in appearance between plugs which contained ECFCs alone or ECFCs and MSCs combined ( Fig. 1B) . Although plugs that contained ECFCs only were whitish from a gross morphology point of view, dual-cell transplanted plugs appeared well vascularized resulted in an 8-to 18-fold increase in ECFC engraftment. ECFC engraftment was better supported by coimplantation with AdBM-MSCs (17-fold), fBM-MSCs (16-fold), or fPL-MSCs (15-fold). mPL-MSCs (8-fold) had a weaker, albeit still significant, level of support for ECFC engraftment (Fig. 1C) . 
Coimplantation increased human vessel density
It is well documented that ECFCs can form new functional vessels after engraftment (19) . We identified GFP + human vessels based on their tubular structure ( Fig. 2A, B) , and confirmed their human origin as they costained with anti-human CD144, CD49f, and CD31 antibodies ( Fig. 2A ).
Quantification revealed that transplantation of ECFCs alone in rag1 2/2 mice resulted in few humanized vessel structures ( Fig. 2B ). On coimplantation, AdBM-MSCs strongly supported neovessel structure formation (21.4fold compared to ECFCs alone). This was the highest gain in ECFC-derived vessel formation, compared to fBM-MSCs (18.0-fold), fPL-MSCs (19.4-fold), or mPL-MSCs (8.3-fold). Of importance, on costaining with mouse/ human CD49f and mouse CD31, ECFC-derived neovessels were shown to be linked to the host murine vasculature ( Fig. 2C ). Finally, we ruled out any direct contribution of the human MSC populations to the vessels formed. After 7 d, none of the MSC populations (identified by human lamin A/C staining) injected alone in Matrigel plugs formed any vessel-like structures or was positive for the CD144 or CD49f endothelial markers (Supplemental Fig. 2A, B) .
MSCs augment ECFC survival in vitro in stress conditions
To assess the benefit of coimplantation on cell survival under stress conditions, ECFCs were cultured under serum starvation conditions with or without MSCs. AdBM-MSCs were used for these in vitro studies, given their marked effect on ECFC function in vivo. After 48-h culture in EBM (no serum or growth factors), cells were assessed by flow cytometry, and GFP + ECFCs were counted (Fig. 3A) . Coculture with MSCs significantly improved ECFC survival compared with control (8.4fold; Fig. 3B ).
To further assess the impact of MSC paracrine activity on ECFC survival, Transwell assays (Corning, Inc.) were designed, and ECFCs and MSCs were cultured in the same well, but in separate compartments without direct contact (Fig. 3C ). The number of ECFCs was determined after 48-h culture in starvation conditions (EBM). Of interest, the presence of AdBM-MSCs increased ECFC survival compared to the control (1.9-fold; Fig. 3D ). These results Fig. 3 ). Scale bar, 50 mm. F, G ) Immunostaining of cocultured cells confirmed that ECFCs changed their morphology on coculture to form elongated mesenchymallike structures that expressed CD31, CD144, and CD49f markers (F ), whereas ECFCs cultured alone in EGM2 (G) maintained a cobblestone-like morphology. Scale bar, 50 mm.
suggest that a paracrine factor produced by AdBM-MSCs explains some part of the improved survival of ECFC in stress conditions.
To replicate the effects of MSC-secreted factors on ECFC survival, MSC-CM was harvested and delivered to the ECFCs directly or after 25-fold concentration (Fig. 3E) ; however, this did not result in improved ECFC survival at 48 h under stress conditions (Fig. 3F ), which suggests that MSC-secreted factors either play a negligible part in ECFC survival in stress conditions or have a short half-life to allow their use in conditioned medium.
To ensure the validity of our findings in vivo, CM was harvested from MSCs cultured in EBM for 2 d and then 5 3 10 5 ECFCs supplemented with MSC-CM or culture medium (EBM) alone were implanted in rag1 2/2 mice (each group, n = 3 mice, 6 plugs). After 7 d, ECFC engraftment with MSC-CM did not affect cell survival compared to control (Fig. 3G, H ; P = 0.3). Therefore, in contrast to coimplantation, CM had no significant impact on ECFC engraftment. This seemed to indicate that ECFC survival and proliferation mostly rely on direct contact with MSCs or require continuous cross-talk with MSCs.
Coculture with MSCs drastically reduces ECFC proliferation
Having established the effect of MSCs on ECFC survival under stress conditions, we next sought to understand the cellular and molecular drivers of improved vessel formation. Indeed, after the initial stress of implantation in an ischemic environment, surviving cells displayed improved vasculogenic potential if coinjected with MSCs. Hence, we explored whether MSCs had a benefit beyond the immediate postimplantation stress period.
MSCs and GFP-tagged ECFCs were coseeded in EGM2 (complete medium) for 48 h, and GFP-tagged ECFCs were counted via flow cytometry. To ensure that ECFCs were not contaminated by persistent MSCs carried over from coculture, cell sorting was performed for GFP and CD90 clearly distinguishing ECFC (GFP + CD90 2 ) from the MSC populations (CD90 + GFP 2 ) in cocultures after stringent exclusion of doublets (Fig. 4A) . In nonconfluent conditions, although ECFCs strongly proliferated in coculture with MSCs (2-fold increase in number in 48 h), this was less than if ECFCs were cultured alone (4-fold increase in number; Fig. 4B ). Coculture with AdBM-MSCs consistently reduced ECFC proliferation at 48 h and later time points (11.3 6 2.3-fold increase in number of ECFCs alone vs. 3.4 6 0.9fold for ECFCs cocultured with MSCs). These results were not caused by contact inhibition, as it was significant before confluence. To evaluate the importance of cell-cell contact compared to paracrine factors in normal culture conditions, Transwell experiments were performed in EGM2 (Fig. 4C, D) . As with the directcontact culture system, ECFC growth was reduced, albeit to a lesser degree (1.6 6 0.4; P , 0.01). This further excluded contact inhibition as a mechanism for the slower proliferation.
In coculture with MSCs, ECFCs adopt a mesenchymal morphology
ECFCs cocultured with MSCs changed their morphology and formed elongated capillary-like structures ( Fig. 4E, F) . In live-imaging experiments, the morphology change toward elongated vessel-like structures was confirmed and found to rely on contact with MSCs (Supplemental Fig. 3 ). ECFC morphology did not change if cultured in Transwells in the presence, but not in contact, with MSCs. The cells maintained their cobblestone-like morphology (data not shown).
Immunostaining for CD31, CD144, and CD49f confirmed expression of endothelial markers on GFPtagged ECFCs (Fig. 4F, G) . This clearly showed that in coculture conditions with MSCs, ECFCs organized into longitudinal structures reminiscent of vascular tubes, not into cobblestone configurations (Fig. 4F , G and Supplemental Fig. 3 ). Of note, flow cytometry revealed that the expression of CD31 was not affected in ECFCs cocultured with MSCs, although expression of CD34 increased significantly (Fig. 5A, B) . No expression of CD31 endothelial markers was observed in GFP-negative MSCs when they were cocultured with ECFCs ( Fig. 5A ). Real-time qPCR showed increased expression of CD31 and CD34 genes in cocultured ECFCs (Fig. 5C ). In addition, MSCs alone did not express endothelial markers after 3 d culture in EGM2, as confirmed by immunostaining ( Fig. 5D ).
Short contact with MSC primes ECFCs toward a differentiated phenotype
Given the profound changes occurring in ECFC morphology and proliferation, we next hypothesized that a short coculture would affect ECFC progenitor function. We termed ECFCs cocultured with MSCs during a short (4 d) period as being primed. Primed ECFCs were then assayed for self-renewal and endothelial potential (Fig. 6A) .
After 4 d of coculture with MSCs or culture alone in nonconfluent conditions, primed ECFCs and ECFCs, respectively, were sorted and cultured as single cells. Upon flow sorting, 384 single GFP + CD90 2 cells were cultured individually. After 2 wk, each single well was examined. Primed ECFCs had a reduced capacity to form HPP colonies, suggesting that they had lost, in part, their selfrenewal potential (Fig. 6B, C) . ECFCs and primed ECFCs formed similar numbers of endothelial clusters or LPP colonies, suggesting that the loss of HPP colonies accounted at least in part for the reduced number of cells.
Our earlier work showed that the self-renewing fraction among ECFCs has a delayed capacity to form tubes in vitro Figure 6 . Primed ECFCs enhance endothelial differentiation and have less self-renewal potential. A) ECFCs were cultured alone or with MSCs (primed ECFCs), and then the ECFCs were sorted based on the GFP + CD90 2 expression phenotype and exclusion of doublets. B, C ) After 14 d, endothelial colonies were classified as ECs, LPP-EPCs, or HPP-EPCs. Primed ECFCs had reduced capacity to form HPP-EPC colonies, suggesting less self-renewal potential. Scale bar, 100 mm (n = 3 independent cell culture experiments in triplicate). Error bars, SD. **P , 0.01. D, E ) Primed ECFCs showed higher capillary formation capacity 12 and 24 h after seeding on Matrigel in vitro. Scale bar, 100 mm (n = 4). *P , 0.05. F, G) Primed-ECFC showed a higher engraftment level than in ECFCs alone (red: lamin A/C. Data are means 6 SD. Scale bar, 20 mm. *P , 0.05, in Matrigel plugs in vivo in immunodeficient mice but less than after MSC-ECFC cotransplantation; ***P , 0.005.
in Matrigel (30) . Primed-ECFCs showed significantly higher capillary formation capacity at 12 and 24 h after seeding, further suggesting the loss of the progenitor fraction (Fig. 6D, E) . Finally, we implanted primed ECFCs in Matrigel plugs into rag1 2/2 mice. Primed-ECFCs showed a higher level of engraftment compared to ECFCs alone (12.1 6 4.4-fold; Fig. 6F, G) , but less than with MSC-ECFC cotransplantation. Overall, this reduced proliferation and self-renewal but improved capillary formation capacity suggests that primed ECFCs have less of a progenitor function and more of a differentiated phenotype.
Priming in the mesenchymal niche significantly alters ECFC gene expression
To better understand changes occurring in ECFCs during coculture with MSCs, we compared ECFCs cultured alone to ECFCs cultured with MSCs for 4 d. Both populations were sorted and subjected to RNA extraction and gene expression array analysis ( Fig. 7A ; n = 5 independent experiments for each condition). Unsupervised clustering distinguished primed ECFCs from ECFCs not exposed to MSCs (Fig. 7B ). After correction for multiple testing, 1669 genes were differentially expressed between the 2 conditions. The main pathways involved were cell cycle and DNA damage, platelet activation reflecting cell adhesion changes, and EMT (Supplemental Table 1 ). The cell cycle appeared to be the top biologic function, explaining a substantial part of the gene expression differences. Along with cell proliferation experiments, microarray data confirmed in primed ECFCs lower expression of genes involved in the cell cycle such as CDC25C (0.173), CDC45 (0.423), PCNA (0.233), and CCNA2 (0.283).
Priming of ECFCs resulted in the high expression of extracellular matrix proteins such as periostin (POSTN, 10.13) and collagen (COL1A1, 4.83, and -2, 4.33), as well as adhesion molecules such as P-selectin (SELP, 5.33), LUM (2.03), ITGB4 (1.93), VCAN (4.33), and HAS2 (5.83) in primed ECFCs ( Table 2 ).
Of interest, several genes up-regulated in primed ECFCs related to their improved endothelial function. EGR1 (3.23) has been associated with improved angiogenesis in the endothelium (31); JUNB (2.53) contributes to production of VEGF and is up-regulated in activated endothelial cells (32) , PLVAP (2.63, regulating the endothelial permeability), and endothelial stabilization genes Similarly, NOTCH signaling was shown to be significantly involved with many of its target genes up-regulated in primed ECFCs, as confirmed by real-time qPCR. The NOTCH pathway involved genes, such as NOTCH1 (19.13), NOTCH4 (3.83), DLL1 (7.73), DLL4 (9.43), and in particular, the NOTCH pathway target genes, HES1 (7.83), and HEY1 (4.93) were up-regulated in primed ECFCs.
NOTCH signaling was shown to be significantly involved, with many of its target genes up-regulated in primed ECFCs as confirmed by real-time qPCR (Fig. 7C ). Higher expression of microarray top genes using real-time qPCR was confirmed with much larger differences. Realtime qPCR confirmed that POSTN (15.43), SELP (14.13), VCAN (4.93), EGR1 (35.43), HAS2 (5.33), and APLNR (4.13) genes were up-regulated in primed ECFCs (Fig.  7D) . The importance of the EMT pathway was reflected in higher levels of SNAI1 and SNAI2 expression by primed ECFCs. Finally, we evaluated genes involved in the regulation of the cell cycle in ECFCs (30) . Primed ECFCs expressed high levels of CDKN2A (P16, 2.93), CDKN1A (P21, 3.43), CDKN1C (P57, 7.03), and IL33 (IL33, 4.73) (Fig. 7E) . Results were produced from 3 independent cell culture experiments in triplicate.
Inhibition of NOTCH signaling partially counteracts mesenchymal priming of ECFCs
To evaluate the role of NOTCH signaling in this MSC-ECFC interaction and its priming phenotype, we cocultured MSCs and ECFCs in the presence of the g-secretase inhibitor DAPT for 4 d (Fig. 8A) . DAPT prevents the cleavage of the NOTCH intracellular domain and its translocation to the nucleus upon ligand engagement.
Pharmacological inhibition of the NOTCH pathway in this system was effective, as it significantly reduced the expression of the target genes HES1 (53) and HEY1 (4.53) in primed ECFCs. NOTCH inhibition further reduced expression of NOTCH1, NOTCH4, and DLL4 to levels observed in nonprimed ECFCs (Fig. 8B) . Similarly, most of the highly differentially expressed genes between primed and nonprimed ECFCs neared their baseline levels in nonprimed ECFCs. Indeed NOTCH inhibition significantly reduced EGR1 (6.23), POSTN (1.83), and VCAN (3.53) gene expression levels as well as the EMT gene SNAI2 (Fig. 8C ) in 3 independent experiments in triplicate. However, NOTCH inhibition did not affect the cell cycle regulators CDKN1A, CDKN2A, CDKN1C, or IL33 in primed ECFCs (Fig. 8D) .
Functionally, NOTCH pathway inhibition restored at least partially the cobblestone-like morphology of ECFCs ( Fig. 8E ) and significantly reduced the capacity of primed ECFCs to have an elongated morphology. However, it did not restore the proliferation potential of ECFCs (Fig. 8F) . DAPT-treated cells were also subjected to assays to test their self-renewal and endothelial potential (Fig. 8G, H) . Again, primed ECFCs showed higher capillary formation capacity, which was largely reversed upon incubation with DAPT at 12 h (11-fold) and 24 h after seeding (20-fold; Fig. 8G ). To evaluate the self-renewal potential in the presence of DAPT, we performed single-cell colonyformation assays. As expected, 2 wk after culture, primed ECFCs demonstrated a reduced number of HPP colonies compared with normal ECFCs (Fig. 8H ). Coculturing ECFCs with MSCs in the presence of DAPT resulted in reduced HPP endothelial colonies compared with dual-cell cultures incubated with DMSO, but did not fully restore the colony formation of cells compared to ECFCs cultured alone (Fig. 8H ). Altogether, inhibition of NOTCH signaling using DAPT partially reversed mesenchymal priming of ECFCs.
DISCUSSION
Restoring the blood supply to ischemic tissues would greatly benefit patients who have vascular diseases. Accordingly, transplantation of ECFCs with de novo vessel formation potential has attracted considerable interest over the past decade (8, 9) . A major translational hurdle, however, has been the low in vivo engraftment capacity of these cells in ischemic tissues (14, 15) . We examined the importance of a developmentally-relevant mesenchymal niche in enhancing ECFC engraftment and function in vivo.
In particular, we showed that short-term contact with MSCs can prime ECFCs to adopt a more differentiated phenotype, with reduced self-renewal potential yet enhanced adhesion and tube formation potential. This allowed significantly better engraftment in vivo. Furthermore, dissection of the gene expression changes occurring on contact with MSCs clearly established a mesenchymallike transition driven at least in part by NOTCH signaling that could be reversed with pharmacological inhibition.
In vivo, pericytes contribute to stabilizing the vasculature (35) (36) (37) (38) and it is widely documented that adult MSCs may have a perivascular origin (37) . As a result, several authors have attempted codelivery of MSCs and ECFCs were sorted and subjected to in vitro tube formation assay, a single-cell clonogenic assay, or total RNA extraction and qPCR. B) NOTCH inhibition reduced the expression of NOTCH1, NOTCH4, DLL4, HES1, and HEY1 almost to levels observed in nonprimed ECFCs, as measured by qPCR. C ) NOTCH inhibition reduced expression of the highly differentially expressed genes in primed ECFCs to near baseline levels in nonprimed ECFCs, EGR1 (6.23), POSTN (1.83), and VCAN (3.53). D) NOTCH inhibition did not affect expression of cell cycle regulators CDKN1A, CDKN2A, CDKN1C, or IL33 in primed ECFCs. E ) NOTCH pathway inhibition allowed restoration of the cobblestone-like morphology of ECFCs, at least in part. F ) DAPT-incubated primed ECFCs had proliferation potential similar that of to DMSO-incubated primed ECFCs. Results are presented as fold changes in number of cells reported to the number of seeded cells. G) Primed ECFCs showed higher capillary formation capacity on Matrigel, a potential that was reversed upon incubation with DAPT at 12 h (11-fold) and 24 h (20-fold) after seeding. H ) Coculturing ECFCs with MSCs in the presence of DMSO showed reduced numbers of HPP-EPC colonies compared with normal ECFCs after 2 wk. Incubation with DAPT did not restore the colony formation of cells and the number of cells was significantly less than when the ECFCs were cultured alone (n $ 3 independent experiments). Data are means 6 SD. ns, not significant. *P , 0.05; **P , 0.01; ***P , 0.005. endothelial cells. ECFC cotransplantation with MSCs has been shown to result in enhanced regeneration in an osteogenic context with improved neovascularization (39) . MSCs from different sources, however, are known to have different self-renewal and differentiation capacities. Lin et al. (40) investigated the capacity of different murine MSC populations on ECFC engraftment in a Matrigel plug model. They demonstrated no substantive difference in proangiogenic secretomes and proangiogenic capacity with different tissue-specific murine MSCs. All investigated MSC types were able to improve vascularization compared to ECFCs alone, albeit at different levels. AdBM-MSCs showed the maximum enhancement potential, whereas mPL-MSC had the least, although we acknowledge that some between-donor variation cannot be excluded. We confirmed results from the literature (18, 41) , in that MSCs could not form new vessels after implantation.
The molecular contributors to interactions between MSCs and ECFCs to date are unclear. Although the paracrine effects were evaluated in several studies (42, 43 ) the impact of cell-cell contact has been investigated to a much smaller extent. Through a systematic analysis in vivo and in vitro, including Transwell and CM experiments, we confirmed that the MSC-modulated effects on ECFCs were several fold. Those related to the cell morphology and tube formation were strictly contact dependent as shown by Transwell experiments. On the other hand, survival and proliferation effects of MSCs were partly observed in the absence of direct contact. In support of this, Pedersen et al. (44) reported HUVEC quiescence and maturation after coseeding with MSCs. Although Transwell experiments showed some impact of MSCs on ECFC survival, it was not reproduced by MSC-CM, suggesting that factors secreted by MSCs either had a short half-life and needed to be produced continuously to be maintained or had only a minor effect on ECFC survival. Indeed, we did not observe significant changes in the number of ECFCs upon treatment with MSC-CM in vivo, in contrast to prior results (45) . Admittedly, differences in experimental design such as the use of serum or the shorter observation period in vivo could account for such differences.
Even short-term contact with MSCs resulted in a rapid change in phenotype that persisted in culture after the removal of MSCs. We conclude that the consequence of the priming effect reduced endothelial cell self-renewal capacity by reducing the number of HPP-ECFC colonies. Tube formation in vitro is also an indication of a more differentiated phenotype. Indeed, this was accompanied by a change in ECFC morphology from Figure 9 . Mesenchymal priming of ECFCs is a complex process involving multiple pathways. Some of the priming response result from MSC-secreted molecules (enhanced cell survival in starvation condition and cell cycle repression), whereas others are strictly cell-cell contact-dependent, such as ECFC differentiation and morphology. Current results showed NOTCH signaling contributes in mesenchymal priming of ECFCs. Ligand-receptor interaction during MSC-ECFC contact results in NOTCH signaling activation. NOTCH intracellular domain releases and translocates to the nucleus upon ligand engagement. Inhibition of NOTCH signaling using the g-secretase inhibitor DAPT prevents the cleavage of the NOTCH intracellular domain. NOTCH activation through mesenchymal priming stimulates a more differentiated endothelial phenotype and a mesenchymal-like morphology that is associated with expression of some specific genes including ECM genes, but does not affect the cell cycle. Other mechanisms are suggested to contribute to ECFC mesenchymal priming but remain elusive.
cobblestone-like to elongated capillary-like structures. Live imaging showed that ECFCs preferentially adhered to MSC and adopted an elongated morphology. Stem cell priming has been reported to improve cardiomyocyte commitment (46) , myogenesis potential (47) , and immunomodulatory effects (48) . In regard to ECFC therapy, several studies have assessed the benefit of priming ECFCs ex vivo by using proangiogenic factors (49) (50) (51) . ECFC priming with erythropoietin enhanced their angiogenic potential and increased their survival on implantation via the phosphoinositide 3-kinase-Akt pathway. Zemani et al. (50) reported improved therapeutic potential by preconditioning EPCs with stromal cell-derived factor (SDF)-1 (51) . In accordance with our findings, this study showed that priming leads to increased EPC differentiation into tubular structures and more potential to revascularization through CXCR4/SDF-1 interaction.
Despite these attempts at ECFC priming, the molecular machinery underpinning this process remains unclear. Our study gives first insights into the molecular contributors to ECFC priming by MSCs-for example, changes in gene expression related to the cell cycle and replication of DNA machinery. The contribution of the NOTCH pathway in endothelial differentiation has been supported by others (52, 53) . In addition NOTCH pathway activation can regulate endothelial cell proliferation (54) through upregulation of the cell cycle regulatory genes CDKN2A, CDKN1A, and CDKN1C (30, 54), as found in the current study. In a previous study, our group demonstrated an important mechanism of quiescence in vitro among the self-renewing fraction of ECFCs (30) . A distinguishing feature of primed ECFCs from the self-renewing ECFC fraction is that cycle regulators in primed ECFCs do not depend on NOTCH signaling, as pharmacological inhibition did not change their level of expression, maintaining a low level of colony-forming cells, as well as reduced proliferation. Given the strong up-regulation of NOTCH1, it is likely that this receptor is preferentially engaged during the priming. NOTCH ligand-receptor interaction and NOTCH activation requires cell-cell contact (55), potentially explaining observations in direct coculture but not in Transwell assays. NOTCH pathway inhibition in MSC-ECFC cocultures changed much of the morphology and tube formation potential of primed ECFCs but did not affect proliferation and colony formation. These latter attributes were shown to depend in part on paracrine factors that did not require cell-cell contact. It is thus expected that other pathways must be activated to fully replicate all observations during MSC-ECFC cocultures ( Fig. 5 ).
An additional group of genes differentially expressed on ECFC priming with MSCs includes ECM and adhesion molecule genes involved in vascular remodelling, such as HAS2, POSTN, SELP, and VCAN. These could be regrouped in our pathway analysis as indicative of EMT. The elongated mesenchymal morphology of ECFCs upon priming and up-regulation of SNAI1 and SNAI2, as well as the cell adhesion molecules, HAS2, SELP, SELE, SELL, and many other integrin molecules (56) , align in part with the mesenchymal phenotype acquired during EMT. Indeed, POSTN has been recognized as a marker and a key inducer of EMT (57, 58) . It was the top upregulated gene in primed ECFCs according to microarray results. However, this mesenchymal morphology was not the result of a complete transition, as endothelial genes such as CD31 or CD34 were expressed at a higher level in primed ECFCs cocultured with MSCs. It has been suggested that NOTCH stimulates an EMT, by transforming cells from progenitor to differentiated state (54, 59) . In agreement, priming in the presence of a NOTCH inhibitor reduced expression of SNAI2, cell adhesion molecules and POSTN and reduced the elongated mesenchymal morphology.
CONCLUSIONS
We have provided evidence of the importance of the mesenchymal niche in ECFC engraftment. Through improved resistance to stress conditions and transition to a mesenchymal more differentiated phenotype in part related to activated NOTCH signaling ( Fig. 9 ), ECFCs that have been primed with MSCs have enhanced engraftment and capillary formation potential. Altogether, ECFC priming offers a new approach for potential translational application, particularly in situations where rapid vascularization might be needed.
